EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING

被引：0
|
作者：
Capehorn, M. [1 ]
Hallen, N. [2 ]
Hunt, B. [3 ]
机构：
[1] Rotherham Inst Obes, Rotherham, S Yorkshire, England
[2] Novo Nordisk AS, Soborg, Denmark
[3] Ossian Hlth Econ & Commun, Basel, Switzerland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB42
引用
收藏
页码：S512 / S512
页数：1
相关论文
共 50 条
  • [41] The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
    Samuel J. P. Malkin
    Monika Russel-Szymczyk
    Marek Psota
    Lucia Hlavinkova
    Barnaby Hunt
    Advances in Therapy, 2019, 36 : 2034 - 2051
  • [42] ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM COST-EFFECTIVENESS ANALYSIS BASED ON SUSTAIN 7
    Malkin, S. J.
    Belbute, D. G.
    Hunt, B.
    Hoxer, C. S.
    Martin, V
    VALUE IN HEALTH, 2018, 21 : S129 - S129
  • [43] The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
    Ehlers, Lars H.
    Lamotte, Mark
    Ramos, Mafalda C.
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (01) : 29 - 37
  • [44] Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
    Lei Liu
    Zhen Ruan
    Carolina Oi Lam Ung
    Yawen Zhang
    Yang Shen
    Sheng Han
    Ruxu Jia
    Jingtao Qiao
    Hao Hu
    Lixin Guo
    Diabetes Therapy, 2023, 14 : 93 - 107
  • [45] Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting
    Martin, Virginia
    Vidal, Josep
    Malkin, Samuel J. P.
    Hallen, Nino
    Hunt, Barnaby
    ADVANCES IN THERAPY, 2020, 37 (10) : 4427 - 4445
  • [46] Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
    Liu, Lei
    Ruan, Zhen
    Ung, Carolina Oi Lam
    Zhang, Yawen
    Shen, Yang
    Han, Sheng
    Jia, Ruxu
    Qiao, Jingtao
    Hu, Hao
    Guo, Lixin
    DIABETES THERAPY, 2023, 14 (01) : 93 - 107
  • [47] COST-EFFECTIVENESS OF ONCE WEEKLY DULAGLUTIDE 1.5 MG VERSUS ONCE DAILY LIRAGLUTIDE 1.8 MG FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CHINA
    Han, S.
    Guo, W. J.
    Wang, K.
    McKaig, S.
    Strizek, A. A.
    Shi, L. W.
    VALUE IN HEALTH, 2019, 22 : S167 - S167
  • [48] Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
    Ruan, Zhen
    Ung, Carolina Oi Lam
    Shen, Yang
    Zhang, Yawen
    Wang, Weihao
    Luo, Jingyi
    Zou, Huimin
    Xue, Yan
    Wang, Yao
    Hu, Hao
    Guo, Lixin
    DIABETES THERAPY, 2022, 13 (10) : 1737 - 1753
  • [49] Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting
    Virginia Martín
    Josep Vidal
    Samuel J. P. Malkin
    Nino Hallén
    Barnaby Hunt
    Advances in Therapy, 2020, 37 : 4427 - 4445
  • [50] Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
    Zhen Ruan
    Carolina Oi Lam Ung
    Yang Shen
    Yawen Zhang
    Weihao Wang
    Jingyi Luo
    Huimin Zou
    Yan Xue
    Yao Wang
    Hao Hu
    Lixin Guo
    Diabetes Therapy, 2022, 13 : 1737 - 1753
12345